ORUM Market Cap ($216.70 Million)
Market Cap & Net Worth: ORUM (475830)
ORUM market cap. ORUM (KQ:475830) has a market capitalization of $216.70 Million (₩319.76 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #16023 globally and #568 in its home market, demonstrating a -6.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORUM's stock price ₩15060.00 by its total outstanding shares 21232368 (21.23 Million). Also see 475830 cash generation efficiency for how efficiently the company converts equity into cash flow.
ORUM Market Cap History (2025–2026)
ORUM market cap history from 2025 to 2026. Data shows change from $1.73 Billion to $216.70 Million (-30.65% CAGR). Check ORUM share price for real-time trading data and today's change.
ORUM Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ORUM's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 475830 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
73.27x
ORUM's market cap is 73.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.73 Billion | $23.56 Million | -$41.97 Billion | 73.27x | N/A |
Competitor Companies of 475830 by Market Capitalization
Companies near ORUM in the global market cap rankings as of November 4, 2026. Also see ORUM assets under control for a full breakdown of the balance sheet.
Key companies related to ORUM by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of ORUM (2025–2026)
Market capitalization of ORUM from 2025 to today. Between 2025 and today, ORUM's market cap moved from $1.73 Billion to $ 216.70 Million, with a yearly change of -30.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩216.70 Million | -87.45% |
| 2025 | ₩1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of ORUM was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $216.70 Million USD |
| MoneyControl | $216.70 Million USD |
| MarketWatch | $216.70 Million USD |
| marketcap.company | $216.70 Million USD |
| Reuters | $216.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more